CSL有限公司在早盘交易中股价大幅下挫10.8%，此前该公司宣布下调2026财年的业绩展望，并确认了高达50亿澳元（约合33亿美元）的资产减值损失。
这家生物技术巨头在向市场发布的声明中指出，由于全球血浆采集成本持续上升，以及旗下部分业务单元面临的市场挑战超出预期，公司决定对相关资产价值进行重新评估。减值主要涉及部分研发项目及生产设施的账面价值调整。
管理层同时调整了对2026财年的业绩指引，将原先预期的营收增长区间从“高个位数百分比”下调至“中个位数百分比”，并将核心利润增长预期从“双位数百分比”调整为“高单位数百分比”。公司表示，此次调整是出于对运营环境更为审慎的评估，尤其是血浆供应链成本的持续压力。
市场分析师普遍认为，此次大幅减值及展望下调超出预期，直接引发了投资者对公司短期盈利能力和资产质量的担忧，导致股价在开盘后遭遇抛售。尽管公司强调其长期战略和核心血浆制品业务的韧性保持不变，但短期财务指标的恶化显然动摇了市场信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.